Postherpetic Neuralgia News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Global Postherpetic Neuralgia API Manufacturers, Marketed and Phase III Drugs Landscape Report 2018 ... - Business Wire (press release)



Global Postherpetic Neuralgia API Manufacturers, Marketed and Phase III Drugs Landscape Report 2018 ... 
Business Wire (press release)
Postherpetic Neuralgia - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018' report provides comprehensive insights about marketed and Phase III products for Postherpetic Neuralgia . The report includes information of marketed ...

and more » 


New Shingles Vaccine Found to Be More Effective | Everyday Health - Everyday Health, Inc. (blog)



Everyday Health, Inc. (blog)
 
New Shingles Vaccine Found to Be More Effective | Everyday Health 
Everyday Health, Inc. (blog)
A newly available shingles vaccine is more effective at preventing the painful condition, a development that may convince more people to get vaccinated.
New shingles vaccination keeps the pox from striking back in older ... Calgary Herald

all 2 news articles » 


Shingrix: Is the Hype Justified? - Medscape



Medscape
 
Shingrix: Is the Hype Justified? 
Medscape
Hi. My name is Paul Offit. I'm talking to you from the Vaccine Education Center at Children's Hospital of Philadelphia. I want to talk about a newly licensed and recommended shingles vaccine. Shingles, as you know, is a reactivation of an original ...

 


CHMP Backs Shingles Vaccine Shingrix for Adults 50 and Older - Medscape



Medscape
 
CHMP Backs Shingles Vaccine Shingrix for Adults 50 and Older 
Medscape
The European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) voted to recommend granting marketing authorization for recombinant, adjuvanted herpes zoster vaccine (Shingrix, GlaxoSmithKline [GSK] Biologicals, SA] to ...
GSK's shingles vaccine gets green light from EMA panel Reuters
Working to launch its shingles vaccine in the U.S., GlaxoSmithKline ... FiercePharma
GSK's Shingrix Gets Positive CHMP Opinion For Prevention Of Shingles Markets Insider
Stock Market Wire  -London South East (blog) 
all 8 news articles » 


Recognizing the pain of shingles, treating the virus - taosnews



taosnews
 
Recognizing the pain of shingles, treating the virus 
taosnews
Most people fully recover from shingles. However, a condition in which the nerve continues to be damaged after the rash has healed can occur. It is called post-herpetic neuralgia (PHN). Only 10 percent of shingles cases will lead to PHN. Pain ...

 


Reviewing the Effectiveness of Lidocaine for the Management of Chronic Pain - Clinical Pain Advisor



Clinical Pain Advisor
 
Reviewing the Effectiveness of Lidocaine for the Management of Chronic Pain 
Clinical Pain Advisor
The authors conducted a review of research investigating the safety and efficacy of systemic lidocaine ? delivered either intravenously or through a patch (5% lidocaine) ? for the prevention and treatment of chronic pain. The literature search ...

 


Natural Healing - Waterford Today



Natural Healing 
Waterford Today
The treatment Versatis has been in the news a lot recently. Versatis contains lignocaine, a local anaesthetic, which provides pain relief. It's specifically prescribed for issues associated with post-herpetic neuralgia (PHN), a painful skin complaint ...

and more » 


Shot may help shield against shingles - Science Daily



Shot may help shield against shingles 
Science Daily
According to Dr. Rosamilia, early treatment not only can reduce the pain and severity of the disease, but also can help prevent potential side effects like eye problems, infection, and a condition called post-herpetic neuralgia, which causes pain ...

 


Former XenoPort Chief Medical Officer, Richard Kim, MD, Joins NDA Partners as Expert Consultant - PR Web (press release)



Former XenoPort Chief Medical Officer, Richard Kim, MD, Joins NDA Partners as Expert Consultant 
PR Web (press release)
Dr. Kim is an expert in a wide range of indications, including multiple sclerosis, psoriasis, restless legs syndrome, amyotrophic lateral sclerosis, alcohol use disorder, and post-herpetic neuralgia. Dr. Kim is a well-diversified pharmaceutical ...

 


What's Propelling Acorda Therapeutics Inc (NASDAQ:ACOR) After Higher Shorts Reported? - BZ Weekly



BZ Weekly
 
What's Propelling Acorda Therapeutics Inc (NASDAQ:ACOR) After Higher Shorts Reported? 
BZ Weekly
Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company has market cap of $1.18 billion. The firm markets Ampyra , an oral drug to improve ...
Acorda Therapeutics Inc (NASDAQ:ACOR) Sellers Increased By 4.48% Their Shorts Reurope
Acorda Therapeutics, Inc. - ACOR - Stock Price Today - Zacks Zacks

all 19 news articles »